FRANK WESTAD: Open Payments
NPI 1033204698 · GREENWICH, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$475 in 26 payments from 8 companies in 2025. Trend: 2023 $299 · 2024 $384 · 2025 $475
Food & beverage: $475
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $146 |
| Lilly USA, LLC | 5 | $97 |
| GlaxoSmithKline, LLC. | 5 | $81 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Novo Nordisk Inc | 2 | $33 |
| Exact Sciences Corporation | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
Products named: FARXIGA, MOUNJARO, REXULTI, SHINGRIX, TRELEGY ELLIPTA, AIRSUPRA, Cologuard Collection Kit, CAPLYTA.
Industry payments across NY — which companies pay providers there.
